IDYA
Price
$37.59
Change
+$0.14 (+0.37%)
Updated
Sep 11 closing price
Capitalization
3.63B
59 days until earnings call
Intraday BUY SELL Signals
RNA
Price
$10.36
Change
+$0.01 (+0.10%)
Updated
Sep 11 closing price
Capitalization
177.21M
81 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs RNA

IDYA vs RNA Comparison Chart in %
View a ticker or compare two or three
VS
IDYA vs. RNA commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and RNA is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($3.63B) has a higher market cap than RNA($177M). IDYA YTD gains are higher at: 8.736 vs. RNA (-85.344). RNA has higher annual earnings (EBITDA): -95.71M vs. IDYA (-212.46M). IDYA has more cash in the bank: 829M vs. RNA (264M). RNA has less debt than IDYA: RNA (1.68M) vs IDYA (29.3M). IDYA has higher revenues than RNA: IDYA (234M) vs RNA (35.8M).
IDYARNAIDYA / RNA
Capitalization3.63B177M2,049%
EBITDA-212.46M-95.71M222%
Gain YTD8.736-85.344-10%
P/E RatioN/AN/A-
Revenue234M35.8M654%
Total Cash829M264M314%
Total Debt29.3M1.68M1,741%
FUNDAMENTALS RATINGS
IDYA vs RNA: Fundamental Ratings
IDYA
RNA
OUTLOOK RATING
1..100
8354
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
11
Undervalued
PROFIT vs RISK RATING
1..100
72100
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
4084
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RNA's Valuation (11) in the null industry is in the same range as IDYA (30). This means that RNA’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (72) in the null industry is in the same range as RNA (100). This means that IDYA’s stock grew similarly to RNA’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as RNA (97). This means that IDYA’s stock grew similarly to RNA’s over the last 12 months.

IDYA's Price Growth Rating (40) in the null industry is somewhat better than the same rating for RNA (84). This means that IDYA’s stock grew somewhat faster than RNA’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as RNA (100). This means that IDYA’s stock grew similarly to RNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYARNA
RSI
ODDS (%)
Bearish Trend 1 day ago
61%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 19 days ago
74%
Bullish Trend 10 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
71%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (IDYA: $37.59 vs. RNA: $10.36)
Brand notoriety: IDYA and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 56% vs. RNA: 119%
Market capitalization -- IDYA: $3.63B vs. RNA: $177.21M
IDYA [@Biotechnology] is valued at $3.63B. RNA’s [@Biotechnology] market capitalization is $177.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green while RNA’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • RNA’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than RNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while RNA’s TA Score has 6 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 5 bearish.
  • RNA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RNA is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -5.69% price change this week, while RNA (@Biotechnology) price change was -26.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 10, 2026.

RNA is expected to report earnings on Dec 02, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IDYA
Daily Signal:
Gain/Loss:
RNA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QTUM147.411.80
+1.24%
Defiance Quantum ETF
IHY21.42-0.02
-0.12%
VanEck Intl Hi Yld Bd ETF
HYBL27.85-0.04
-0.14%
State Street® Blackstone High Income ETF
COMB28.58-0.36
-1.23%
GraniteShares Blmbrg CmdtyBrdStr NoK1ETF
GAVA18.18-0.29
-1.57%
Grayscale Avalanche Staking ETF

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
+0.10%
DYN - RNA
64%
Loosely correlated
-1.14%
DSGN - RNA
48%
Loosely correlated
-1.15%
IDYA - RNA
48%
Loosely correlated
+0.37%
PBYI - RNA
48%
Loosely correlated
-0.55%
NTLA - RNA
42%
Loosely correlated
-1.59%
More